Abstract

Context.—More than 90% of testicular neoplasms originate from germ cells. Testicular germ cell tumors (GCTs) are a heterogeneous group of neoplasms with diverse histopathology and clinical behavior.

Objective.—To help the readers distinguish various subtypes of GCTs, to highlight the clinical manifestations and pathologic features of these tumors, and to review several newly developed immunohistochemical markers for GCTs.

Data Sources.—Review of the pertinent literature and our experience.

Conclusions.—The etiology of GCTs is largely unknown. Cytogenetic studies suggest a different pathogenesis for each group of infantile/prepubertal GCTs, postpubertal GCTs, and spermatocytic seminoma. Unclassified intratubular germ cell neoplasia is the precursor of all GCTs, excluding spermatocytic seminoma and infantile/prepubertal GCTs. Seminoma, the most common GCT in adults, does not occur before 5 years of age. Spermatocytic seminoma, a tumor of elderly men, typically has an indolent clinical behavior, but rarely it undergoes sarcomatous transformation associated with an aggressive behavior. Embryonal carcinoma is the most common component in mixed GCTs. Eighty percent or more of embryonal carcinoma component and vascular invasion are recognized predictors of occult metastasis for clinical stage I mixed GCTs. Most patients with prepubertal yolk sac tumor, the most common pediatric GCT, have stage I disease at presentation. Most choriocarcinomas present with metastatic symptoms because of the propensity for rapid hematogenous dissemination. Teratomas in children regardless of maturity and dermoid cysts in adults are benign; in contrast, teratomas in adults have a malignant behavior. With appropriate therapy, the majority of testicular GCTs are curable.

Testicular tumors are the most common malignancies among American men between the ages of 20 and 39 years.1,2 The American Cancer Society has estimated that in the year 2006, 8250 men will develop testicular cancers and 370 men will die of these tumors in the United States.3 Testis tumors comprise approximately 1% of all cancers in men,3,4 but only about 0.1% of cancer deaths in males3 because the majority of these tumors are curable.5 

More than 90% of testicular neoplasms originate from germ cells.6 The incidence of testicular germ cell tumors (GCTs) increases shortly after the onset of puberty and peaks in the fourth decade of life with a median age of 34 years at diagnosis.7 The incidence varies among different races and various geographic locations. It is 5 times more frequent in white men compared with African American men.8 Among nations with the highest reported incidence are Scandinavia, Germany, and New Zealand.9 

Despite several recognized risk factors in the development of GCTs (eg, cryptorchidism or a prior history of GCT), the pathogenesis of germ cell neoplasms including the contributing role of environmental factors or genetic susceptibility remains unknown. Reports from the epidemiologic studies in the United States and Europe have revealed an increase in the incidence of GCTs during the past several decades,10,11 but the reason for such a trend is unclear.

Testicular GCTs are a heterogeneous group of neoplasms with diverse histopathology and variable clinical course and prognosis. This diversity is best reflected in various systems offered to classify these tumors.12–17 Currently the most comprehensive and widely accepted system of classification is the one proposed by the World Health Organization,18 which is summarized in Table 1.

Table 1. 

2004 World Health Organization Histologic Classification of Germ Cell Testis Tumors

2004 World Health Organization Histologic Classification of Germ Cell Testis Tumors
2004 World Health Organization Histologic Classification of Germ Cell Testis Tumors

There is some evidence that the origin and biology of prepubertal and postpubertal testicular GCTs are distinct from each other. First, the distribution pattern of GCTs in adults and children is different. Testicular neoplasms in adult patients often consist of seminoma, embryonal carcinoma, or mixed testicular GCTs. In the pediatric population, yolk sac tumor and teratoma are the most frequent tumors; on the contrary, seminoma and embryonal carcinoma are rare.19 Non-GCTs, which account for less than 10% of testicular neoplasms in adults, comprise as high as one third of testis tumors in children. Furthermore, although there is a strong association between postpubertal testicular tumors and intratubular germ cell neoplasia, such association has not been observed in prepubertal GCTs.

Genetic studies have shown that postpubertal testis tumors are often aneuploid with a consistent chromosomal abnormality composed of a gain of short arm of chromosome 12, usually in the form of an isochromosome, i(12p).20 In contrast tumors arising in prepubertal gonads are typically unassociated with 12p amplification and tend to be diploid. For these reasons, testicular GCTs have been also divided into 3 biologically distinct categories of infantile/prepubertal GCTs, postpubertal GCTs, and spermatocytic seminoma. Spermatocytic seminoma is a disease of elderly men and appears to have a different pathogenesis than seminoma.

Germ cell tumors have been traditionally separated into seminomatous and nonseminomatous tumors. This division, however, is essentially for clinical purposes because of some differences in the management approach and prognosis of these 2 groups of tumors.

INTRATUBULAR GERM CELL NEOPLASIA, UNCLASSIFIED

There is convincing evidence that intratubular germ cell neoplasia, unclassified (IGCNU), is the precursor of all invasive GCTs with the exception of spermatocytic seminoma and infantile/prepubertal GCTs.21,22 Intratubular germ cell neoplasia, unclassified, has been identified in the vicinity of GCTs in about 90% of cases.23,24 Additionally, there is an increased prevalence of IGCNU in clinical conditions at risk for testicular cancer, including cryptorchidism (2%–4%),25,26 oligospermic infertility (0–1.1%),27,28 and contralateral testis of patients with testicular cancer (4.9%–5.4%).29–31 The prevalence of IGCNU in healthy males, in contrast, is only 0.43%.32 

The IGCNU cells are both morphologically and immunohistochemically similar to seminoma cells. This observation has led to the hypothesis that seminoma is the direct derivative of IGCNU and a common pathway in the development of all other GCTs.33 Cytogenetic studies have supported a similar chromosomal constitution in IGCNU cells and the adjacent invasive component, with the major difference being the gain of 12p in the invasive part.34–36 It is therefore hypothesized that the critical genetic event leading to invasion is acquisition of excess genetic material on the short arm of chromosome 12.

The term unclassified implies the presence of an uncommitted undifferentiated cell that is capable of progressing toward an invasive GCT. Furthermore, it is used to distinguish this lesion from other types of intratubular germ cell neoplasia (eg, intratubular embryonal carcinoma or intratubular yolk sac tumor). Intratubular germ cell neoplasia, unclassified, is known to be the precursor of most adult GCTs; on the other hand, other types of intratubular germ cell neoplasia are developed as an outcome of pagetoid intratubular spread of their invasive counterpart in the testicular parenchyma adjacent to a preexisting GCT.

Pathologic Features

Testes with IGCNU are usually normal in size but can be smaller than normal. Histologically, IGCNU is characterized by large primitive atypical cells that are usually twice the size of normal germ cells. These cells lie along the thickened basement membrane of atrophic seminiferous tubules (Figure 1) or may replace the entire tubules. The malignant germ cells have large nuclei with prominent nucleoli and abundant clear cytoplasm that is rich in glycogen, demonstrable by a periodic acid–Schiff (PAS) stain. Because normal germ cells are not stained with PAS, this stain may help to distinguish IGCNU cells from normal cells.

Figure 1.

Intratubular germ cell neoplasia, unclassified, showing large atypical germ cells lying along the basement membrane of atrophic seminiferous tubules (hematoxylin-eosin, original magnification ×400).Figure 2. Intratubular germ cell neoplasia, unclassified, showing strong immunoreactivity for D2-40 with a membranous pattern in atypical intratubular germ cells (immunoperoxidase, original magnification ×200).Figure 3. Seminoma with a nested growth pattern separated by lymphocyte-rich fibrovascular trabeculae (hematoxylin-eosin, original magnification ×100).Figure 4. Seminoma characterized by large uniform evenly dispersed tumor cells displaying clear cytoplasm and distinct cell membrane (hematoxylin-eosin, original magnification ×400).Figure 5. Tubular variant of seminoma composed of hollow tubular structures lined by characteristic seminoma cells with clear cytoplasm and distinct cytoplasmic border (hematoxylin-eosin, original magnification ×200).Figure 6. Spermatocytic seminoma characterized by a diffuse proliferation of polymorphous tumor cells, composed of small (lymphocyte-like), intermediate, and large cells with characteristic spireme-type chromatin pattern (hematoxylin-eosin, original magnification ×400).

Figure 1.

Intratubular germ cell neoplasia, unclassified, showing large atypical germ cells lying along the basement membrane of atrophic seminiferous tubules (hematoxylin-eosin, original magnification ×400).Figure 2. Intratubular germ cell neoplasia, unclassified, showing strong immunoreactivity for D2-40 with a membranous pattern in atypical intratubular germ cells (immunoperoxidase, original magnification ×200).Figure 3. Seminoma with a nested growth pattern separated by lymphocyte-rich fibrovascular trabeculae (hematoxylin-eosin, original magnification ×100).Figure 4. Seminoma characterized by large uniform evenly dispersed tumor cells displaying clear cytoplasm and distinct cell membrane (hematoxylin-eosin, original magnification ×400).Figure 5. Tubular variant of seminoma composed of hollow tubular structures lined by characteristic seminoma cells with clear cytoplasm and distinct cytoplasmic border (hematoxylin-eosin, original magnification ×200).Figure 6. Spermatocytic seminoma characterized by a diffuse proliferation of polymorphous tumor cells, composed of small (lymphocyte-like), intermediate, and large cells with characteristic spireme-type chromatin pattern (hematoxylin-eosin, original magnification ×400).

Immunoprofile

Most IGCNU cells stain for placental-like alkaline phosphatase (PLAP)37–40 usually with a membranous and cytoplasmic pattern. Placental-like alkaline phosphatase is an enzyme that in addition to IGCNU is present in embryonal carcinoma, seminoma, and several other GCTs but is usually absent in normal germ cells. The IGCNU cells are also positive for c-Kit (CD117)41,42 and p53 but are negative for cytokeratins, human chorionic gonadotropin (hCG), or α-fetoprotein (AFP). OCT3/4, also known as POU5F1, is a recently recognized marker for GCTs.43 In adult testis, positive immunostaining for OCT3/4 is an indicator for the presence of IGCNU, seminoma, and/or embryonal carcinoma.44 OCT3/4 immunostain highlights IGCNU with a nuclear staining pattern and has proved to be a sensitive and specific marker for detection of IGCNU in biopsy specimens.44,45 D2-40, an antibody raised against a transmembrane mucoprotein called podoplanin, stains IGCNU cells46–48 (Figure 2) as well as lymphatics. Therefore, this antibody can be used to confirm the presence or absence of IGCNU adjacent to invasive GCTs and also to highlight lymphatic invasion.

Clinical Course and Management

Spontaneous regression of IGCNU generally does not occur. Without intervention, about 50% of IGCNU cases will progress to an invasive GCT within 5 years of the diagnosis of IGCNU,31 but on long-term follow-up almost all patients will develop an invasive GCT.49 

There is controversy in regard to the management of IGCNU. Orchiectomy clearly provides the highest success rate and perhaps is the therapy of choice in unilateral IGCNU.49,50 Several studies have shown the effectiveness of localized low-dose radiotherapy as compared with chemotherapy in eradication of IGCNU.51,52 Radiation therapy has been considered by some authorities as the treatment of choice in bilateral IGCNU. Although radiotherapy leads to permanent infertility, it has the benefit of preserving hormonal function of the testis. Yet others have advocated surveillance on the basis that if an invasive GCT develops, it will be easy to detect and manage with available effective treatments.

SEMINOMATOUS GCT

There are 2 types of seminomatous tumors: (1) classic seminoma and its variants and (2) spermatocytic seminoma.

Classic Seminoma and Its Variants

Seminoma is the most common testicular germ cell neoplasm, accounting for approximately 50% of these tumors.53–55 In addition, seminoma is a recognizable component in a large proportion of mixed GCTs.54 

Clinical Features

The peak incidence is between 34 to 45 years, which is about 1 decade later than that of most other GCTs.54 Before puberty, seminoma is extremely rare; in fact, it does not occur in the first decade of life especially in children younger than 5 years. Most patients present with a typically painless testicular enlargement. Gynecomastia and infertility are rare presenting symptoms. A fraction of cases may present with symptoms of metastases.56 Extension to the spermatic cord or epididymis is seen in less than 10% of patients,54,56 and in 2% of cases both testes are involved.

Pathologic Features

Grossly, seminomas are firm when intact, but after sectioning they are soft at palpation with a light tan, moist, homogenous appearance. They may form a single nodule or may be multinodular separated by thick connective tissue septae. Small areas of necrosis or petechial hemorrhage are frequently present, but extensive necrosis, hemorrhage, and cyst formation are uncommon. Gross appearance of seminoma is rather typical and relatively easy to recognize, but similar gross features can be seen in spermatocytic seminoma and testicular lymphoma.

In histologic examination, seminoma cells typically have a solid or nested growth pattern separated by thin fibrovascular trabeculae rich in T-cell lymphocytes (Figure 3). Only 1% of seminomas are devoid of lymphoid infiltration.57 The individual tumor cells are large, uniform, round to polygonal, and evenly spaced without nuclear overlapping (Figure 4). Seminoma cells display a distinct cell membrane and usually a lightly eosinophilic to clear cytoplasm because of the presence of glycogen, demonstrable by a PAS stain. The nuclei contain 1 or more prominent nucleoli. Mitoses are variable but usually readily identifiable.

Ill-defined granulomatous reactions are frequently seen in seminomas. These reactions at times are so intense that they obscure the seminoma cells.56 Under these circumstances, the presence of IGCNU in the peritumoral testicular parenchyma is a helpful observation in resolving the diagnostic difficulty. Such reactions, however, more commonly occur in metastatic than in primary locations. In such cases, immunohistochemical staining may contribute to the identification of the nature of lesion.

Histologic Variants of Seminoma

Seminoma with syncytiotrophoblastic giant cells is a recognized variant of seminoma by the World Health Organization classification system.18 Syncytiotrophoblasts, which stain positively for hCG and cytokeratin, are seen in approximately 20% of seminomas.58,59 The presence of these cells does not impart an adverse prognosis60 but does correlate with mild elevation of serum hCG, which is generally normalized after orchiectomy. A persistent elevation of serum hCG level following orchiectomy or a high level of serum hCG, in contrast, may indicate a hidden focus of choriocarcinoma.

There are a variety of histologic variants of seminoma characterized by different growth patterns. These histologic profiles, including cribriform/microcystic,61 tubular,62–65 and intertubular,66 may mimic other pathologic entities67 and create diagnostic confusion. When cribriform/ microcystic pattern is the dominant picture, seminoma may superficially resemble yolk sac tumor. The tubular variant (Figure 5) can simulate Sertoli cell tumor. The intertubular variant exhibits a diffuse intertubular growth of seminoma cells similar to the pattern of testicular involvement by hematopoietic neoplasms. Despite these variable growth patterns, seminoma cells retain their cytologic features; therefore, the key to the differential diagnosis is attention to cytologic details of tumors cells. In questionable circumstances, immunohistochemical staining can help to make an accurate diagnosis.

On rare occasions, seminomas may be entirely infarcted and seen as a mass of “ghost” cells suspicious for neoplasm. Florentine et al68 reported a case of necrotic seminoma in which a Masson trichrome stain plus PLAP immunostain improved the histology and helped to establish the diagnosis. The authors concluded that, in the presence of architectural distortion in a tumor suspicious for seminoma, selected immunostains might aid in arriving at the right diagnosis.

Seminoma with high mitotic rate, also known as anaplastic or atypical seminoma, constitutes 5% to 15% of seminomas.69,70 Histologically, it is characterized by increased mitotic activity (3 or more mitoses per 1 high-power field),69 a greater nuclear pleomorphism, and a paucity of the lymphocytic infiltrate. The prognostic significant of this entity, however, is controversial. Although some studies reported a more aggressive behavior and a lower survival rate in anaplastic seminomas compared with classic seminomas,69,71 several other studies failed to demonstrate such differences when the 2 groups were compared stage by stage.72–74 One possible explanation is the confounding effect of a higher stage at clinical presentation in anaplastic seminoma compared with classic seminoma.

Immunoprofile

Immunohistochemically, seminomas are positive for PLAP75 and c-Kit (CD117)76,77 but are negative for epithelial membrane antigen, Ki-1 (CD30),78 AFP, and hCG.79 The transcription factor OCT3/4 is a robust diagnostic marker for seminoma as well as for embryonal carcinoma.80 OCT3/4 has been shown to be a highly sensitive and specific marker for the diagnosis of both tumors in metastatic sites as well.81 Recent studies have reported that podoplanin, recognized by the commercially available D2-40 monoclonal antibody,47,48 is a specific marker for seminoma because unlike OCT3/4, it is not expressed by embryonal carcinoma. Cytokeratin is usually negative but may be focally positive in up to 40% of seminomas.82 

Treatment of Seminomatous Tumors

Because the management of seminoma and other GCTs following radical inguinal orchiectomy largely depends on the stage of the lesions, before discussion on the management, we shortly review the staging system of testis tumors.

Staging of Testicular Tumors

In 1997, an internationally agreed-on prognostic factor– based staging classification, applicable to both seminoma and nonseminomatous tumors, was published.83 This well-validated classification has now been incorporated into the tumor-node-metastasis (TNM) (Table 2) and the American Joint Committee on Cancer staging systems (Table 3).84 Staging of testis tumors considers the TNM system of classification plus levels of prognostically important tumor-specific serum markers including hCG, AFP, and lactate dehydrogenase. Serum levels of the liver enzyme lactate dehydrogenase reflect tumor turnover.

Table 2. 

TNM System in Testis Tumors*

TNM System in Testis Tumors*
TNM System in Testis Tumors*
Table 3. 

Stage Grouping of Testis Tumors*

Stage Grouping of Testis Tumors*
Stage Grouping of Testis Tumors*

In summary, stage I is a localized disease in which the tumor is limited to the testis and paratesticular tissues; stage II is defined by the involvement of regional (retroperitoneal) lymph nodes, which is further divided into 2 major groups of nonbulky or low-volume (lymph node mass ≤ 5 cm) and bulky or high-volume (lymph node mass > 5 cm) disease; stage III includes metastasis to nonregional lymph nodes or disseminated disease. Although pathologic staging based on the TNM system is largely applicable to localized disease, and to retroperitoneal lymph node dissections, it really cannot be applied to nonsurgical metastatic disease. Metastatic disease in patients with seminoma is usually assessed radiographically in terms of computed tomography/magnetic resonance imaging size of the metastatic lymph nodes in the retroperitoneum. Thus, the decision to give radiation or chemotherapy is made according to the clinical staging based on the radiographic findings.

Management of Seminomatous Tumors

Following radical inguinal orchiectomy, the traditional treatment of classic seminoma with clinical stage I (localized disease) is low-dose radiation to the regional lymph nodes that achieves a cure rate of more than 90%.9 Other management options available to patients with stage I seminoma include surveillance and adjuvant chemotherapy. However, with surveillance alone, 15% to 20% of such cases may relapse.85 In a pooled analysis of 638 patients with stage I seminoma from 4 large surveillance studies, the primary tumor size (cutoff of 4 cm) and the rete testis invasion were 2 important prognostic factors for relapse.86 A nationwide Danish surveillance study for stage I testicular seminoma similarly showed the tumor size as a significant independent prognostic factor for relapse. In that series, the 4-year survival rates were 94%, 82%, and 64% for tumors measuring less than 3 cm, 3 to 6 cm, and more than 6 cm, respectively.87 Chemotherapy is the treatment of choice for patients with bulky retroperitoneal involvement and all stage III cases, which results in a complete response rate of approximately 90% in these patients.88,89 

Spermatocytic Seminoma

Spermatocytic seminoma is an uncommon germ cell neoplasm that accounts for 1% to 2% of all testis tumors.90 Spermatocytic seminoma exclusively develops in the testis and has no ovarian or extragonadal counterpart.56 Classic seminoma and spermatocytic seminoma are believed to have a different pathogenesis and separate cell of origin. The cell origin of spermatocytic seminoma appears to be more differentiated than that of seminoma and capable of spermatogenesis.91 Cytogenetic studies have shown that spermatocytic seminoma is either diploid or aneuploid with loss of chromosome 9 rather than isochromosome 12p, which is seen in other postpubertal GCTs.92 

Clinical Features

Spermatocytic seminoma typically occurs in men older than 50 years of age (median, 55 years), although it may be occasionally seen in younger patients.93 This tumor classically presents as a painlessly enlarging testicular mass. Although most textbooks have reported the incidence of bilaterality in spermatocytic seminoma to be as high as 10%,90 compared with only 1.6% in all other GCTs,94,95 our personal experience has shown a more or less similar frequency to that of other GCTs including classic seminoma. Spermatocytic seminoma is not associated with cryptorchidism, IGCNU, or other germ cell neoplasia90,96; therefore, it is not seen as a component in mixed GCTs.

Spermatocytic seminoma often has an indolent natural history. The risk of metastasis is extremely rare.96,97 However, in a small fraction of cases (approximately 6%), the tumor may undergo sarcomatous dedifferentiation, which is associated with an aggressive behavior.98–101 Of significance, in cases with sarcomatous dedifferentiation and distant metastasis, the metastases were exclusive to the sarcomatous components.100 

Pathologic Features

Grossly, spermatocytic seminomas are well circumscribed, yellow-gray, soft, gelatinous, and sometimes mucoid. The gross appearance may be similar to that of classic seminoma or testicular lymphoma.102 Foci of cystic change, hemorrhage, and necrosis may be evident. In cases with sarcomatous transformation, the tumor may appear dull gray, fleshy, and more solid.56 

Histologically, spermatocytic seminoma consists of a diffuse proliferation of polymorphic cells supported by a scanty or edematous stroma. The tumor cells are classically of 3 types (Figure 6): small (lymphocyte-like), intermediate (10–30 μm), and large or giant (50–100 μm), which are usually uninucleated but rarely multinucleated. Intermediate cells are often the predominant cell type and comprise the bulk of the tumor. The nuclei of large and intermediate cells often display a typical spiral deposition of chromatin similar to that seen in spermatocytes. The nuclei of small cells are rather dense. The cytoplasm of tumor cells is eosinophilic to amphophilic and does not contain glycogen. A high mitotic activity is often appreciated. Intratubular spread of spermatocytic seminoma in the adjacent seminiferous tubules may be present.

The sarcomatous component of spermatocytic seminoma is usually composed of undifferentiated spindle cells, but differentiated patterns such as rhabdomyosarcoma and chondrosarcoma have also been reported.98–101 An “anaplastic” variant of spermatocytic seminoma, characterized by a predominance of anaplastic cells with prominent nucleoli, extensive necrosis, and vascular or tunical invasion without sarcomatous elements, has been described in a small series.103 In all cases, foci of classic spermatocytic seminoma within the tumor were present. Although the clinical course of patients in that series was indolent and essentially similar to that of typical spermatocytic seminoma, the prognostic significance of this variant needs to be determined in larger series with long-term follow-up.

Immunoprofile

Many of the markers including OCT3/4 and PLAP, which are demonstrated in other types of GCTs, have not been detected in spermatocytic seminoma.84,104–106 Spermatocytic seminoma cells do not react with hCG, AFP, leukocyte common antigen,104 or CD30. However, consistent expression of c-Kit106 and germ cell marker VASA107 as well as focal cytoplasmic staining for CAM 5.2 in some cases have been described.105 

Differential Diagnosis

The differential diagnoses of spermatocytic seminoma mainly include classic seminoma and malignant lymphoma. The presence of lymphocyte-rich fibrovascular trabeculae, granulomas, and the uniformity of a single-cell population distinguish classic seminoma from spermatocytic seminoma. Large cell lymphoma, the most common testicular malignancy in the same age group, is characterized by an interstitial growth pattern. Cytologically, lymphoma cells displays a fine nuclear chromatin pattern as compared with the typical spiremelike chromatin distribution of spermatocytic seminoma.102 In difficult cases, immunohistochemical staining for lymphoid markers can aid to differentiate the 2 entities.

Clinical Course and Management

The prognosis of spermatocytic seminoma is remarkably good with a very low tendency for metastasis. Although low-dose radiation to the abdomen following orchiectomy has been traditionally the treatment of choice, surveillance is currently becoming the preferred management option by most authorities.93,108 Spermatocytic seminoma with sarcomatous transformation necessitates aggressive treatment with chemotherapy although the prognosis remains very poor despite chemotherapy.98,100 

NONSEMINOMATOUS GCT

Nonseminomatous GCTs are composed of embryonal carcinoma, yolk sac tumor, immature or mature teratoma, choriocarcinoma, and other rare trophoblastic tumors. These tumor types are often seen together in various combinations, referred to as mixed GCTs, which may also include seminoma. The words nonseminomatous and mixed GCTs are usually used interchangeably in daily clinical practice.

Embryonal Carcinoma

Pure embryonal carcinoma, although relatively uncommon, is the second most common single-cell–type GCT after seminoma. Embryonal carcinoma as a component, however, is present in more than 80% of mixed GCTs.54,109 

Clinical Features

Pure embryonal carcinoma occurs most frequently between 25 and 35 years of age, which is 10 years earlier than the age range for seminoma. Embryonal carcinoma is rare after the age of 50 years and does not occur in infancy. Most patients present with a painless unilateral enlarging testicular mass. Approximately two thirds of cases have retroperitoneal lymph node or distant metastases at the time of diagnosis.110 

Pathologic Features

Grossly, embryonal carcinoma often presents as a poorly demarcated mass with a soft gray-tan cut surface, frequently associated with large foci of hemorrhage and necrosis.56 Extension into the cord and epididymis is not uncommon.

On microscopic examination, embryonal carcinoma displays variable growth patterns, including solid, syncytial, acinar, tubular, or papillary arrangement (Figure 7, A).56 Marked anaplasia, numerous mitoses including abnormal forms, and cellular overlapping characterize this tumor (Figure 7, B). The neoplastic cells are polygonal, undifferentiated, and epithelial looking with large vesicular and empty-looking nuclei and thick, distinct nuclear membrane. The cytoplasm is usually abundant and finely granular with a nondistinct cell border.

Figure 7.

A, Embryonal carcinoma displaying a papillary pattern of growth (hematoxylin-eosin, original magnification ×100). B, Embryonal carcinoma cells characterized by marked anaplasia and abnormal mitotic figures (hematoxylin-eosin, original magnification ×400)

Figure 7.

A, Embryonal carcinoma displaying a papillary pattern of growth (hematoxylin-eosin, original magnification ×100). B, Embryonal carcinoma cells characterized by marked anaplasia and abnormal mitotic figures (hematoxylin-eosin, original magnification ×400)

Intratubular germ cell neoplasia, unclassified, and less commonly intratubular embryonal carcinoma,111 may be seen in the adjacent testicular parenchyma. Vascular/lymphatic invasion in the peritumoral tissue is an important feature to document. True vascular/lymphatic invasion, however, should be distinguished from the artifactual intravascular implants, which easily happen during tissue sectioning because of the cellular and friable nature of the tumor.

Immunoprofile

Embryonal carcinomas are commonly positive for cytokeratin112,113 but negative for epithelial membrane antigen, which can help distinguish a metastatic embryonal carcinoma from a somatic carcinoma. Placental-like alkaline phosphatase40,113 and OCT3/480 are both sensitive markers for embryonal carcinoma but do not discriminate against seminoma. D2-40, which stains seminoma, in contrast, does not label embryonal carcinoma.47,48 Ki-1 (CD30), which is also a sensitive marker for embryonal carcinoma40,78 (Figure 8), stains no other GCTs including seminoma or yolk sac tumor. CD30 expression, however, is frequently lost in metastatic embryonal carcinoma after chemotherapy.111 The embryonal carcinoma cells are usually negative for carcinoembryonic antigen, hCG, and CD117 (c-Kit).76 When distinction of seminoma from the solid pattern of embryonal carcinoma is a diagnostic consideration, a cytokeratin cocktail, CD30, D2-40, and CD117 immunostaining used in combination may help the differential diagnosis.76 Although AFP may occasionally stain scattered tumor cells,59,113 the presence of AFP, either immunohistochemically or in the serum, is generally regarded as an evidence of yolk sac differentiation.

Figure 8.

Embryonal carcinoma showing strong membranous immunoreactivity for CD30 (immunoperoxidase, original magnification ×200)

Figure 8.

Embryonal carcinoma showing strong membranous immunoreactivity for CD30 (immunoperoxidase, original magnification ×200)

Yolk Sac Tumor

Yolk sac tumor is a germ cell neoplasm that differentiates in the direction of the embryonic yolk sac, allantois, and extraembryonic mesenchyme. It is the most common testicular neoplasm in the pediatric population, accounting for approximately half of the prepubertal testis tumors.19,114,115 Childhood yolk sac tumor does not appear to be associated with cryptorchidism56 or IGCNU. Yolk sac tumor in children is almost always seen in the pure form. On the contrary, in adults it is seen only admixed with other neoplastic germ cell elements, and the pure form is extremely rare.116 Foci of yolk sac tumor are found in 40% of mixed GCTs in adults.

Clinical Features

In children, the median age at presentation is 16 months (range, newborn to 11 years). Patients usually present with a rapid painless testicular enlargement. About 80% of pediatric yolk sac tumor present with stage I disease.115 

Elevated serum AFP, which is seen in 95% to 100% of patients with testis tumors containing yolk sac elements, is a useful indicator for the presence of this tumor.117 In addition, serial measurement of serum AFP provides a mean for monitoring therapy and for early detection of metastases and recurrences.117 However, caution should be exercised in interpretation of AFP values in children younger than 6 months in whom serum AFP may be physiologically elevated.115,118 

Pathologic Features

On gross examination, yolk sac tumor presents as a solid, lobulated, gray-white, soft ill-defined mass with a gelatinous to mucinous cut surface. Hemorrhage, necrosis, and cystic change may be present.56 

Microscopically, the key to the recognition of yolk sac tumor is the presence of a spectrum of histologic patterns, including reticular (microcystic, vacuolated, honeycomb), macrocystic, endodermal sinus (perivascular, festoon), papillary, solid, glandular-alveolar, myxoid, sarcomatoid (spindle cell), hepatoid, and parietal patterns.56,119 Several of these histologic appearances are usually admixed in a tumor. The reticular-microcystic pattern is the most common feature, occurring in 80% of patients (Figure 9, A).56 The anastomosing thin cords and irregular loose spaces are lined by deceptively benign-appearing flat or cuboidal tumor cells. The cytoplasmic vacuoles within the tumor cells form a meshwork of vacuolated lipoblast-like cells imparting a honeycomb appearance.

Figure 9.

A, Yolk sac tumor with a reticular, microcystic pattern characterized by thin anastomosing cords and loose spaces (hematoxylin-eosin, original magnification ×100). B, Yolk sac tumor showing classic Schiller-Duval bodies with a central fibrovascular core surrounded by malignant cuboidal to columnar cells (hematoxylin-eosin, original magnification ×400)

Figure 9.

A, Yolk sac tumor with a reticular, microcystic pattern characterized by thin anastomosing cords and loose spaces (hematoxylin-eosin, original magnification ×100). B, Yolk sac tumor showing classic Schiller-Duval bodies with a central fibrovascular core surrounded by malignant cuboidal to columnar cells (hematoxylin-eosin, original magnification ×400)

The most distinctive histologic feature is the one forming Schiller-Duval bodies in which a central fibrovascular core is surrounded by malignant cuboidal to columnar cells (Figure 9, B). Another helpful histologic finding is the presence of round, homogeneous diastase-resistant PAS-positive hyaline globules (Figure 10), which contain AFP or α1-antitrypsin. These globules are seen in 85% of cases and represent visceral yolk sac differentiation. Parietal yolk sac differentiation in contrast is characterized by the presence of irregular thick linear eosinophilic basement membrane deposits that are PAS positive but usually negative with AFP.56,120 

Figure 10.

Characteristic round, homogeneous eosinophilic hyaline globules (arrow) in a reticular background of yolk sac tumor (hematoxylin-eosin, original magnification ×200).Figure 11. Choriocarcinoma showing an admixture of syncytiotrophoblasts with multiple nuclei and eosinophilic cytoplasm (long arrow) wrapping around a cluster of cytotrophoblasts (short arrow) (hematoxylin-eosin, original magnification ×200).Figure 12. Immature teratoma composed of an epithelial component surrounded by immature cellular spindle cell stroma (hematoxylin-eosin, original magnification ×200).

Figure 10.

Characteristic round, homogeneous eosinophilic hyaline globules (arrow) in a reticular background of yolk sac tumor (hematoxylin-eosin, original magnification ×200).Figure 11. Choriocarcinoma showing an admixture of syncytiotrophoblasts with multiple nuclei and eosinophilic cytoplasm (long arrow) wrapping around a cluster of cytotrophoblasts (short arrow) (hematoxylin-eosin, original magnification ×200).Figure 12. Immature teratoma composed of an epithelial component surrounded by immature cellular spindle cell stroma (hematoxylin-eosin, original magnification ×200).

Rarely, yolk sac tumors may be entirely composed of 1 single histologic pattern. These histologic variants at times may cause diagnostic challenges; for example, a solid yolk sac tumor can be confused with seminoma or embryonal carcinoma. Immunohistochemical staining in such cases can help to make an accurate diagnosis.

Immunoprofile

Most yolk sac tumors are positive for AFP, but staining is variable and often patchy.38,59,121 Therefore, a negative staining for AFP does not completely exclude a diagnosis of yolk sac tumor. In addition in rare circumstances, a viable yolk sac tumor in the metastatic site may lose its staining for AFP even though the primary tumor is positive for it.122 Staining for cytokeratin, in contrast, is usually diffuse and intensely positive.59,121 Yolk sac tumors are often positive for PLAP and α1-antitrypsin59 but negative for Ki-1,78 hCG, and OCT3/4.45 In a recent report, Glypican 3, a membrane-bound heparin sulfate proteoglycan, has been found to be a very sensitive and relatively specific marker for yolk sac tumor and choriocarcinoma against seminoma, embryonal carcinoma, and teratoma.123 

Treatment

For stage I pediatric patients, the management includes orchiectomy followed by close observation.114,115 Metastatic yolk sac tumor or recurrence should be treated with adjuvant chemotherapy. In children with yolk sac tumor, there is evidence of a predilection for hematogenous spread without lymph node involvement.124 Because only a minority of metastatic prepubertal yolk sac tumors have metastases limited to the retroperitoneum,115 retroperitoneal lymph node dissection is usually reserved for patients with recurrent retroperitoneal masses following chemotherapy.124 Overall, the survival of children with yolk sac tumor is excellent.115 Treatment in adult cases, which is similar to that of other nonseminomatous GCTs, is discussed in the management section.

Choriocarcinoma

Pure choriocarcinoma is extremely rare and accounts for less than 1% of testicular tumors.55,56 However as a component, choriocarcinoma is seen in approximately 8% of mixed GCTs.54 

Clinical Features

Patients with choriocarcinoma are typically in the second or third decades of life. Most cases present with metastatic symptoms, including hemoptysis, gastrointestinal bleeding, or neurologic symptoms rather than a testicular mass. The testis itself usually appears normal or even small because of the regression of the primary site, although depending on the extent of hemorrhage, sometimes it may appear enlarged.56 

Choriocarcinoma is associated with very high values of hCG (>100 000 mIU/mL). Because of cross reactivity of hCG with luteinizing and thyroid-stimulating hormones, some patients may present with symptoms related to endocrine abnormalities, including gynecomastia and hyperthyroidism, respectively.56 

Pathologic Features

On gross examination, choriocarcinoma appears as a hemorrhagic nodule, which is often surrounded by a rim of gray-white tissue at the periphery. Occasionally, the tumor is totally burnt out and only a fibrous scar is discernible.125 

Microscopically, choriocarcinoma is composed of an admixture of 2 cell components, syncytiotrophoblasts and cytotrophoblasts. The individual syncytiotrophoblasts are multinucleated with dark eosinophilic cytoplasm and multiple irregular large hyperchromatic nuclei. The cytotrophoblasts are uniform, medium-sized polygonal cells with abundant cytoplasm, single nuclei, and distinct cytoplasmic border. These cells are usually randomly arranged in solid nests or sheets within a background of hemorrhagic necrosis. In more differentiated areas, syncytiotrophoblasts classically cap or wrap clusters of cytotrophoblasts in a villouslike arrangement (Figure 11).

Monophasic choriocarcinoma is a variant of choriocarcinoma with a monomorphic appearance mainly composed of cytotrophoblasts with inconspicuous syncytiotrophoblastic cells.126 Because cytotrophoblasts without combination with syncytiotrophoblasts are histologically nondescript, a monophasic choriocarcinoma may resemble seminoma, embryonal carcinoma, or the solid variant of yolk sac tumor.

The testicular counterpart of placental site trophoblastic tumor has been described in only a few cases.126,127 These tumors were predominantly composed of a proliferation of intermediate trophoblast. The neoplastic cells showed diffuse immunoreactivity for human placental lactogen and patchy staining for hCG.

Cystic trophoblastic tumors are uncommon lesions described in retroperitoneal resections after chemotherapy in patients with GCTs.128 These lesions consist of circumscribed small cysts lined by a predominance of mononucleated trophoblastic cells with smudged nuclei and infrequent mitotic figures. These lesions appear to have little aggressive potential, and their presence in postchemotherapy resections does not warrant additional treatment.

Of note, scattered syncytiotrophoblasts, which may be seen in about 20% of pure seminomas, should not be misinterpreted as foci of choriocarcinoma. The combination of seminoma with choriocarcinoma is extremely rare in our experience. In addition, we have not seen cases of seminoma with choriocarcinoma without other GCT components.

Immunoprofile

Immunostaining for hCG is constantly positive in syncytiotrophoblasts and also in transitional cells between syncytiotrophoblasts and cytotrophoblasts (intermediate trophoblasts), but it is usually negative in cytotrophoblasts.79 Inhibin129 stains cytotrophoblasts and intermediate trophoblasts. Intermediate trophoblasts, if present, may also stain for human placental lactogen and human leukocyte antigen G, a nonclassical MHC class I antigen.130 Cytokeratin is positive in all of the cell types.131 Vimentin is negative, but carcinoembryonic antigen may be positive in syncytiotrophoblasts.132 The PLAP immunostain is positive in 50% of choriocarcinomas.59 Glypican 3 has been recently demonstrated to be expressed in choriocarcinoma, with stronger immunoreactivity in syncytiotrophoblasts compared with cytotrophoblasts.123 

Prognosis

Because of its predilection for rapid hematogenous dissemination, choriocarcinoma has a worse prognosis than other types of GCT.133 In fact, the prognosis of a pure choriocarcinoma is worse than a “mixed GCT with choriocarcinomatous component.” 14 There is a high incidence of brain metastasis because of the propensity for angioinvasion.134 Choriocarcinoma also commonly involves the retroperitoneal lymph nodes. Both higher values of hCG and greater proportion of choriocarcinoma elements in a GCT are indicative of a more adverse outcome. The management does not differ from the management of any other histologic types of nonseminomatous GCT.

Teratoma

Teratomas are tumors composed of variable types of tissue representing 1 or more of the germinal layers of endoderm, mesoderm, and ectoderm. A tumor composed of only 1 of the 3 germ layers is defined as monodermal teratoma. Mature teratomas are composed of entirely mature well-differentiated components. In contrast, immature teratomas contain embryonic or fetallike tissues, which are typically accompanied by mature elements.

Teratoma occurs in both children and adults, but the biologic behavior of the tumor is substantially different between the 2 groups. In adults, teratoma as a pure neoplasm is uncommon (only 2%–3% of all GCTs); however, as a component, it is present in almost 50% of mixed GCTs.135 In contrast in children, almost all teratomas are pure neoplasms. Teratoma is the second most common prepubertal testicular neoplasm after yolk sac tumor, accounting for 14% of these tumors.19 Most prepubertal teratomas are exclusively composed of mature tissues; nevertheless, all of them behave in a benign manner regardless of the mature or immature nature of their components.19 On the other hand, most postpubertal teratomas are immature, although even purely mature teratomas in adults are at risk of metastases. In other words, the immaturity of teratomatous components is not an indicator of poor biologic behavior in the primary tumor; rather, the age of the patient is important. Most teratomas in children are diploid and lack amplification of short arm of chromosome 12; in contrast, teratomas in postpubertal patients are aneuploid and have isochromosome 12p.136 

Clinical Features

Most prepubertal teratomas are seen in children younger than 4 years with a mean age of 20 months.137 Children typically present with a testicular mass detected by the parents. Most postpubertal cases are young adults presenting with testicular swelling or sometimes with symptoms associated with metastasis. In a series from Indiana, nearly 37% of adult patients with pure teratoma presented with advanced disease.138 

Pathologic Features

On gross examination, teratomas are usually well-circumscribed, solid, firm, nodular or multicystic tumors. Their cut surface is heterogeneous as an expression of variable tissue types. Cysts may be filled with clear serous fluid, pearly gelatinous, or mucinous material.56,102 Cartilage or bony spicules may be grossly discernible. Other grossly recognizable tissues including sebaceous material, hair, and teeth, unlike ovarian teratoma, are not common findings in a testicular teratoma.

In microscopic examination, variable ectodermal, endodermal, and mesodermal tissues admixed in either a disorganized or an organized arrangement are seen. Pure mature teratomas are composed of tissue components resembling adult somatic tissues. The most common components are different types of epithelium, neural tissue, glandular tissue, and cartilage, although virtually any other mature somatic components may be present. Significant cytologic atypia is frequently seen in mature elements of postpubertal teratomas, signifying the aneuploid nature of teratomas in adults.

Immaturity in a teratoma is defined as tissues that cannot be recognized as adult tissue elements (Figure 12) or those that resemble embryonic or fetal tissue. Most immature teratomatous elements of GCTs are cellular spindle mesenchymal components, but immature neural and epithelial elements are also seen. The spindle cells show frequent mitoses.

The vascular invasive component of postpubertal testicular teratoma may include either the teratomatous elements or the precursor cells that have the capacity to differentiate into various cell lines. Therefore, the cellular components of metastatic sites may differ from those of their primary tumor counterpart.

Orchiectomy is curative in pure teratomas in prepubertal patients. The treatment in adults is discussed later with other nonseminomatous GCTs.

Dermoid Cyst

It is controversial whether the rare dermoid cyst of the testis should be classified as a specialized form of mature teratoma or separately. Dermoid cysts characteristically contain cysts lined by keratinizing squamous epithelium associated with skin appendages; however, noncutaneous mature teratomatous elements may also exist in a dermoid cyst.56 In contrast to postpubertal teratoma, dermoid cyst is not associated with IGCNU and also does not have any malignant potential.139 Because teratomas in adults and dermoid cysts are prognostically different, it is important to extensively sample the lesion as well as the uninvolved testicular parenchyma to exclude any immature teratomatous components or IGCNU in the adjacent testis before rendering the diagnosis of dermoid cyst.

Mixed GCTs

Mixed GCTs of the testis are the second most common GCTs in adults (following seminoma), comprising 30% to 50% of the cases.54,113 Tumors that contain seminoma occur at a later age than those without a seminomatous component. Mixed GCTs are rarely seen in prepubertal gonads. Serum elevation of AFP and hCG are common, correlating with the presence of yolk sac tumor elements and syncytiotrophoblastic cells (either singly or as part of choriocarcinoma), respectively.

Grossly, mixed GCTs have a variegated cut surface, reflecting their various tissue components. The most common histologic subtypes in a mixed GCT in order of frequency are embryonal carcinoma, teratoma, yolk sac tumor, seminoma, and choriocarcinoma.140 The histologic appearance of various types of GCTs is identical to that of their pure form. These components are present in variable proportions and in most cases are distributed haphazardly throughout the tumor. Yolk sac tumor is the most frequently overlooked component in a mixed GCT.113 Of all possible histologic combinations, some of the commonly observed forms include embryonal carcinoma/teratoma and embryonal carcinoma/seminoma, reflecting the high frequency of embryonal carcinoma in mixed GCTs.56 In classifying more than 6000 testis tumors, Mostofi141 found that in about 60% of cases, more than 1 histologic elements was present, and the most frequent combination was embryonal carcinoma, yolk sac tumor, teratoma, and syncytiotrophoblasts. Yet in another series, embryonal carcinoma/teratoma was the most commonly observed combination.54 

For mixed GCTs, all components present in the tumor should be listed in the pathology report along with the approximate proportion of each component, in particular that of embryonal carcinoma. The significance of embryonal carcinoma proportion in a mixed GCT is discussed in the section on management of nonseminomatous GCTs.

Polyembryoma and Diffuse Embryoma

Polyembryoma and diffuse embryoma are 2 distinct forms of mixed GCTs. Polyembryoma consists of a mixture of embryonal carcinoma and yolk sac tumor with an associated amnion-like cavity, forming embryoid bodies (Figure 13, A) dispersed in a myxoid stoma. In diffuse embryoma, there is an intermingling of embryonal carcinoma and yolk sac tumor of approximately equal amount (Figure 13, B) arranged diffusely in a necklacelike pattern, in which a single layer of yolk sac tumor covers the embryonal carcinoma as a collaret.56 

Figure 13.

A, Polyembryoma with an embryoid body composed of a mixture of embryonal carcinoma (long arrow) and yolk sac tumor (short arrow) with an associated amnion-like cavity (thick arrow) (hematoxylin-eosin, original magnification ×100). B, Diffuse embryoma characterized by a diffuse intermingling of embryonal carcinoma and yolk sac tumor of approximately equal amount (hematoxylin-eosin, original magnification ×100)

Figure 13.

A, Polyembryoma with an embryoid body composed of a mixture of embryonal carcinoma (long arrow) and yolk sac tumor (short arrow) with an associated amnion-like cavity (thick arrow) (hematoxylin-eosin, original magnification ×100). B, Diffuse embryoma characterized by a diffuse intermingling of embryonal carcinoma and yolk sac tumor of approximately equal amount (hematoxylin-eosin, original magnification ×100)

Treatment of Nonseminomatous Tumors

The treatment for nonseminomatous or mixed GCT largely depends on whether the tumor is localized to the testis or has already metastasized to the retroperitoneal lymph nodes or other sites. Most nonseminomatous GCTs including the pure variants initially metastasize to the retroperitoneum; however, embryonal carcinoma and choriocarcinoma may concomitantly metastasize via vascular invasion and go to distant sites early in the course of disease.142 Initial clinical and radiographic examination (clinical staging) provides clues to the best management of patients with nonseminomatous GCTs.

Because of the high likelihood of retroperitoneal lymph node involvement in patients with nonseminomatous GCTs, the standard management for a localized disease (stage I) is nerve-sparing retroperitoneal lymph node dissection. One of the advantages of this management is to have a true staging procedure that provides a mean for discovery of microscopic retroperitoneal metastasis. Moreover, the procedure alone is curative in a high percentage of cases. Because in the past, retroperitoneal node dissections rendered a high percentage of patients sterile (dry ejaculation), current surgery attempts to preserve the sympathetic and parasympathetic ganglia.

Another management option for localized disease is surveillance. Because some patients may relapse even 1 year after orchiectomy, surveillance requires at least 2 years of follow-up; therefore, it is long and expensive, necessitating monthly chest x-rays, computed tomography/ magnetic resonance imaging of the abdomen every 3 months, and monthly determination of serum markers. Thus, not all patients are good candidates for surveillance; for example, patients with psychiatric problems or drug addicts are not selected for this treatment approach. Many other patients by choice may not elect such prolonged monitoring either. In addition, patients with high risk of occult retroperitoneal metastasis should be excluded from surveillance management. For example, patients with pure embryonal carcinoma are not good candidates because a high percentage may have microscopic metastatic disease. Several studies have shown that the presence of embryonal carcinoma in excess of 80% in the primary tumor and vascular invasion are independent predictors for metastatic disease in patients with clinical stage I mixed GCTs.143–146 The presence of these factors indicates a high-risk group that would be best to exclude from surveillance therapy. Overall, the cure rate for patients with nonseminomatous GCTs in clinical stage I exceeds 95%.9 

The management for metastatic disease to the retroperitoneum (stage II disease) is either retroperitoneal lymph node dissection or chemotherapy. Persistent elevation of serum markers after orchiectomy is usually indicative of metastatic disease. With low-volume disease (nonbulky stage II), both treatments render similar results. As an exception, patients with a prominent teratoma component in the primary usually undergo retroperitoneal lymph node dissection instead of chemotherapy. If these patients are initially treated with chemotherapy, the teratoma component in the retroperitoneum may not respond and continues to grow (growing teratoma syndrome).

Initial chemotherapy is indicated for both bulky stage II and stage III disease, which may be followed by postchemotherapy surgery to eradicate any form of residual disease if present. One clinically important pathologic finding in the evaluation of postchemotherapy residual tissue is the presence of embryonal carcinoma component, which requires implementation of additional chemotherapy.142 Existing teratoma, in contrast, does not impose additional therapy, although the presence of neuroectodermal components in a metastatic site imparts a poor prognosis. Combination chemotherapy has resulted in complete remission in 70% to 80% of patients with distant metastasis.147 

SOMATIC MALIGNANCIES ARISING IN TESTICULAR GCT

Most somatic malignancies arising in testicular GCTs originate from teratomatous component of a mixed GCT, but occasionally they may derive from yolk sac tumor.148,149 Some sarcomas, as described before, may also develop from dedifferentiation of spermatocytic seminoma.98–101 

The somatic malignancies arising in GCTs include various types of sarcomas, including undifferentiated spindle cell tumors or differentiated forms (eg, rhabdomyosarcoma or leiomyosarcoma), primitive neuroectodermal tumor, and carcinomas.148–151 Somatic malignancies can arise in the primary GCT or in the metastatic sites. Somatic tumors confined to the testis generally do not affect the prognosis of GCT; in contrast, those developing in the extratesticular sites, especially primitive neuroectodermal tumor and rhabdomyosarcoma, are likely associated with a poor prognosis.150–152 

Recognition of somatic malignancy from primitive type tissues within teratomas at times can be difficult. Malignancy of mesenchymal elements is characterized by an expansile growth of a pure mesenchymal component (stromal overgrowth), that is, a microscopic field in excess of that viewed with a ×4 objective.153 This criterion is adapted from the definition of stromal overgrowth in malignant transformation of phyllodes tumor of the breast. The presence of stromal invasion, on the other hand, is a useful criterion for defining malignancy of epithelial elements.

Most somatic tumors arising in GCTs have manifested following chemotherapy. Approximately 3% to 6% of patients with metastatic GCTs treated with chemotherapy have shown malignant transformation.148,151 It should be noted that chemotherapy by itself is not a prerequisite for the development of these tumors. Rather, it is the destruction of chemosensitive GCTs that allows the pre-existing somatic malignancies, which are nonresponsive to chemotherapy, to manifest after chemotherapy.148 Surgical resection is the treatment of choice in these tumors.

CONCLUSION

Because decision on the mode of therapy largely relies on pathologic classification of GCTs, pathology reports should include factors that are prognostically significant or have implications for therapeutic decision. The increased interest in surveillance-only management of non– high-risk patients with stage I disease necessitates accurate identification of high-risk patients in whom surveillance is not recommended. Vascular invasion and the proportion of embryonal carcinoma component in a mixed GCT, which are both reliable prognosticators for identification of high-risk patients, can be best evaluated through careful examination of an appropriately sampled testicular neoplasm. The differences in management between seminoma and nonseminoma tumors as well as the potential for only focal existence of nonseminomatous components necessitate adequate sampling of testis tumors for microscopic examination before a diagnosis of seminoma is made (in general, 1 section per 1-cm tumor diameter, including areas with differing appearances). An elevated serum AFP level virtually excludes a diagnosis of pure seminoma, even though microscopic evaluation does not appreciate the nonseminomatous germ cell elements. Although based on a small study, minor elevations of serum AFP (<16 ng/mL) may not be necessarily indicative of the presence of a yolk sac component.154 

To help the clinician select the best treatment for individual patients, the following information should be provided in the pathology report of a testicular GCT: (1) gross features such as tumor size, tumor necrosis, or hemorrhage; (2) local extension, including invasion into the spermatic cord or scrotum, and the status of spermatic cord margin; (3) tumor classification group: seminoma versus nonseminoma (pure or mixed forms); (4) for mixed GCT, a list of various histologic components in the tumor with the approximate percentage of each component; (5) presence or absence of vascular or lymphatic invasion; and (6) presence of IGCNU in uninvolved testicular parenchyma.

Overall, the management of testicular GCTs results in a 90% to 95% cure rate.5 The high success rate with therapy underlines the importance of accurate pathologic diagnosis of GCTs. Pathologists, therefore, should be fully aware of histologic variants of these diverse tumors.

References

References
Wu
,
X.
,
F. D.
Groves
,
C. C.
McLaughlin
,
A.
Jemal
,
J.
Martin
, and
V. W.
Chen
.
Cancer incidence patterns among adolescents and young adults in the United States.
Cancer Causes Control
2005
.
16
:
309
320
.
Devesa
,
S. S.
,
W. J.
Blot
,
B. J.
Stone
,
B. A.
Miller
,
R. E.
Tarone
, and
J. F. Jr
Fraumeni
.
Recent cancer trends in the United States.
J Natl Cancer Inst
1995
.
87
:
175
182
.
Jemal
,
A.
,
R.
Siegel
, and
E.
Ward
.
et al
.
Cancer statistics, 2006.
CA Cancer J Clin
2006
.
56
:
106
130
.
Krain
,
L. S.
Testicular cancer in California from 1942 to 1969: the California Tumor Registry experience.
Oncology
1973
.
27
:
45
51
.
Raghavan
,
D.
Testicular cancer: maintaining the high cure rate.
Oncology (Williston Park)
2003
.
17
:
218
228
.
Talerman
,
A.
Germ cell tumours.
Ann Pathol
1985
.
5
:
145
157
.
Surveillance, Epidemiology, and End Results (SEER) Program.
Available at: www.seer.cancer.gov. SEER*Stat Database: Mortality—All COD, with State, Total U.S. (1969–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Accessed April 2005
.
McGlynn
,
K. A.
,
S. S.
Devesa
,
A. J.
Sigurdson
,
L. M.
Brown
,
L.
Tsao
, and
R. E.
Tarone
.
Trends in the incidence of testicular germ cell tumors in the United States.
Cancer
2003
.
97
:
63
70
.
Bosl
,
G. J.
and
R. J.
Motzer
.
Testicular germ-cell cancer.
N Engl J Med
1997
.
337
:
242
253
.
Zheng
,
T.
,
T. R.
Holford
,
Z.
Ma
,
B. A.
Ward
,
J.
Flannery
, and
P.
Boyle
.
Continuing increase in incidence of germ-cell testis cancer in young adults: experience from Connecticut, USA, 1935–1992.
Int J Cancer
1996
.
65
:
723
729
.
Bergstrom
,
R.
,
H. O.
Adami
, and
M.
Mohner
.
et al
.
Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon.
J Natl Cancer Inst
1996
.
88
:
727
733
.
Collins
,
D. H.
and
R. C.
Pugh
.
Classification and frequency of testicular tumours.
Br J Urol
1964
.
36
:
1
11
.
Mostofi
,
F.
and
E.
Price
.
Tumors of the Male Genital System.
Washington, DC: Armed Forces Institute of Pathology; 1973:16. Atlas of Tumor Pathology; 2nd series, fascicle 8
.
Mostofi
,
F. K.
,
P.
Spaander
,
K.
Grigor
,
C. M.
Parkinson
,
N. E.
Shakkebaek
, and
R. T.
Oliver
.
Consensus on pathological classifications of testicular tumours.
Prog Clin Biol Res
1990
.
357
:
267
276
.
Dixon
,
F.
and
R.
Moore
.
Tumors of the Male Sex Organs. Washington, DC: Armed Forces Institute of Pathology; 1952:50–52. Atlas of Tumor Pathology; 1st series, fascicle 32
.
Grigor
,
K. M.
A new classification of germ cell tumours of the testis.
Eur Urol
1993
.
23
:
93
100
.
Motlik
,
K.
,
A.
Stejskalova
, and
J.
Abrahamova
.
[Classification of germinal tumors of the testis].
Cesk Patol
1986
.
22
:
198
209
.
Eble
,
J. N.
,
G.
Sauter
,
J. I.
Epstein
, and
I. A.
Sesterhenn
.
Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.
Lyon, France: IARC Press; 2004:218–249. World Health Organization Classification of Tumours
.
Weissbach
,
L.
,
J. E.
Altwein
, and
R.
Stiens
.
Germinal testicular tumors in childhood: report of observations and literature review.
Eur Urol
1984
.
10
:
73
85
.
Reuter
,
V. E.
Origins and molecular biology of testicular germ cell tumors.
Mod Pathol
2005
.
18
:(
suppl 2
).
S51
S60
.
Soosay
,
G. N.
,
L.
Bobrow
,
L.
Happerfield
, and
M. C.
Parkinson
.
Morphology and immunohistochemistry of carcinoma in situ adjacent to testicular germ cell tumours in adults and children: implications for histogenesis.
Histopathology
1991
.
19
:
537
544
.
Guinand
,
S.
and
C.
Hedinger
.
[Atypical intratubular germ cells and testicular germ cell tumors in children].
Ann Pathol
1981
.
1
:
251
257
.
Jacobsen
,
G. K.
,
O. B.
Henriksen
, and
Maase H.
von der
.
Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases.
Cancer
1981
.
47
:
2660
2662
.
Dieckmann
,
K. P.
and
N. E.
Skakkebaek
.
Carcinoma in situ of the testis: review of biological and clinical features.
Int J Cancer
1999
.
83
:
815
822
.
Giwercman
,
A.
,
E.
Bruun
,
C.
Frimodt-Moller
, and
N. E.
Skakkebaek
.
Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism.
J Urol
1989
.
142
:
998
1001
.
Rogers
,
E.
,
S.
Teahan
, and
H.
Gallagher
.
et al
.
The role of orchiectomy in the management of postpubertal cryptorchidism.
J Urol
1998
.
159
:
851
854
.
Bettocchi
,
C.
,
C. B.
Coker
,
J.
Deacon
,
C.
Parkinson
, and
J. P.
Pryor
.
A review of testicular intratubular germ cell neoplasia in infertile men.
J Androl
1994
.
15
:(
suppl
).
14S
16S
.
Giwercman
,
A.
,
J. K.
Thomsen
, and
J.
Hertz
.
et al
.
Prevalence of carcinoma in situ of the testis in 207 oligozoospermic men from infertile couples: prospective study of testicular biopsies.
BMJ
1997
.
315
:
989
991
.
Hoei-Hansen
,
C. E.
,
E.
Rajpert-De Meyts
,
G.
Daugaard
, and
N. E.
Skakkebaek
.
Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review.
Ann Oncol
2005
.
16
:
863
868
.
Dieckmann
,
K. P.
and
V.
Loy
.
Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms.
J Clin Oncol
1996
.
14
:
3126
3132
.
von der Maase
,
H.
,
M.
Rorth
, and
S.
Walbom-Jorgensen
.
et al
.
Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.
Br Med J (Clin Res Ed)
1986
.
293
:
1398
1401
.
Linke
,
J.
,
V.
Loy
, and
K. P.
Dieckmann
.
Prevalence of testicular intraepithelial neoplasia in healthy males.
J Urol
2005
.
173
:
1577
1579
.
el Naggar
,
A. K.
,
J. Y.
Ro
,
D.
McLemore
,
A. G.
Ayala
, and
J. G.
Batsakis
.
DNA ploidy in testicular germ cell neoplasms: histogenetic and clinical implications.
Am J Surg Pathol
1992
.
16
:
611
618
.
Summersgill
,
B.
,
P.
Osin
,
Y. J.
Lu
,
R.
Huddart
, and
J.
Shipley
.
Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults.
Br J Cancer
2001
.
85
:
213
220
.
Rodriguez
,
E.
,
J.
Houldsworth
, and
V. E.
Reuter
.
et al
.
Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors.
Genes Chromosomes Cancer
1993
.
8
:
230
236
.
Rosenberg
,
C.
,
R. J.
van Gurp
,
E.
Geelen
,
J. W.
Oosterhuis
, and
L. H.
Looijenga
.
Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas.
Oncogene
2000
.
19
:
5858
5862
.
Loftus
,
B. M.
,
L. G.
Gilmartin
,
M. J.
O'Brien
,
D. N.
Carney
, and
P. A.
Dervan
.
Intratubular germ cell neoplasia of the testis: identification by placental alkaline phosphatase immunostaining and argyrophilic nucleolar organizer region quantification.
Hum Pathol
1990
.
21
:
941
948
.
Jacobsen
,
G. K.
and
B.
Norgaard-Pedersen
.
Placental alkaline phosphatase in testicular germ cell tumours and in carcinoma-in-situ of the testis: an immunohistochemical study.
Acta Pathol Microbiol Immunol Scand A
1984
.
92
:
323
329
.
Koide
,
O.
,
S.
Iwai
,
K.
Baba
, and
H.
Iri
.
Identification of testicular atypical germ cells by an immunohistochemical technique for placental alkaline phosphatase.
Cancer
1987
.
60
:
1325
1330
.
Burke
,
A. P.
and
F. K.
Mostofi
.
Placental alkaline phosphatase immunohistochemistry of intratubular malignant germ cells and associated testicular germ cell tumors.
Hum Pathol
1988
.
19
:
663
670
.
Izquierdo
,
M. A.
,
V.
Van d
, and
J.
Ark-Otte
.
et al
.
Differential expression of the c-kit proto-oncogene in germ cell tumours.
J Pathol
1995
.
177
:
253
258
.
Rajpert-De Meyts
,
E.
and
N. E.
Skakkebaek
.
Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours.
Int J Androl
1994
.
17
:
85
92
.
Looijenga
,
L. H.
,
H.
Stoop
, and
H. P.
de Leeuw
.
et al
.
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.
Cancer Res
2003
.
63
:
2244
2250
.
de Jong
,
J.
,
H.
Stoop
, and
G. R.
Dohle
.
et al
.
Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours.
J Pathol
2005
.
206
:
242
249
.
Jones
,
T. D.
,
T. M.
Ulbright
,
J. N.
Eble
, and
L.
Cheng
.
OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis.
Clin Cancer Res
2004
.
10
:
8544
8547
.
Marks
,
A.
,
D. R.
Sutherland
, and
D.
Bailey
.
et al
.
Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours.
Br J Cancer
1999
.
80
:
569
578
.
Sesterhenn
,
I. A.
,
C. J.
Davis
, and
B.
Furusato
.
M2A antigen (Podoplanin) distribution in prepubertal and adult testes and testicular tumors.
Mod Pathol
2006
.
19
:
159A
.
Abstract 737
.
Badve
,
S.
,
A.
Morimiya
,
B.
Agarwal
,
L.
Cheng
,
T. M.
Ulbright
, and
R.
Saxena
.
Podoplanin: a histological marker for seminoma.
Mod Pathol
2006
.
19
:
129A
.
Abstract 589
.
Giwercman
,
A.
,
Maase H.
von der
, and
N. E.
Skakkebaek
.
Epidemiological and clinical aspects of carcinoma in situ of the testis.
Eur Urol
1993
.
23
:
104
110
.
Montironi
,
R.
Intratubular germ cell neoplasia of the testis: testicular intraepithelial neoplasia.
Eur Urol
2002
.
41
:
651
654
.
Giwercman
,
A.
,
Maase H.
von der
,
J. G.
Berthelsen
,
M.
Rorth
,
A.
Bertelsen
, and
N. E.
Skakkebaek
.
Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients.
J Clin Endocrinol Metab
1991
.
73
:
596
603
.
Dieckmann
,
K. P.
,
A.
Besserer
, and
V.
Loy
.
Low-dose radiation therapy for testicular intraepithelial neoplasia.
J Cancer Res Clin Oncol
1993
.
119
:
355
359
.
Fischer
,
C. G.
,
W.
Waechter
,
S.
Kraus
,
P. E.
Fuentecilla
,
W.
Weidner
, and
J.
Dudeck
.
Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries.
Cancer
1998
.
82
:
775
783
.
Krag Jacobsen
,
G.
,
H.
Barlebo
, and
J.
Olsen
.
et al
.
Testicular germ cell tumours in Denmark 1976–1980: pathology of 1058 consecutive cases.
Acta Radiol Oncol
1984
.
23
:
239
247
.
Ulbright
,
T. M.
Testicular and paratesticular tumors.
In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 14th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:2173–2176
.
Ro
,
J. Y.
,
M. B.
Amin
,
A. A.
Sahin
, and
A. G.
Ayala
.
Tumors and tumorous conditions of the male genital tract.
In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 2nd ed. London, England: Churchill Livingstone; 2000:733–838
.
Jacobsen
,
G. K.
,
H.
von der Maase
, and
L.
Specht
.
Histopathological features of stage I seminoma treated with orchidectomy only.
J Urol Pathol
1995
.
3
:
85
94
.
Hedinger
,
C.
,
A. R.
von Hochstetter
, and
B.
Egloff
.
Seminoma with syncytiotrophoblastic giant cells: a special form of seminoma.
Virchows Arch A Pathol Anat Histol
1979
.
383
:
59
67
.
Niehans
,
G. A.
,
J. C.
Manivel
,
G. T.
Copland
,
B. W.
Scheithauer
, and
M. R.
Wick
.
Immunohistochemistry of germ cell and trophoblastic neoplasms.
Cancer
1988
.
62
:
1113
1123
.
Weissbach
,
L.
,
R.
Bussar-Maatz
, and
U.
Lohrs
.
et al
.
Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study: Seminoma Study Group.
Eur Urol
1999
.
36
:
601
608
.
Damjanov
,
I.
,
D. C.
Niejadlik
,
J. V.
Rabuffo
, and
J. A.
Donadio
.
Cribriform and sclerosing seminoma devoid of lymphoid infiltrates.
Arch Pathol Lab Med
1980
.
104
:
527
530
.
Young
,
R. H.
,
N.
Finlayson
, and
R. E.
Scully
.
Tubular seminoma: report of a case.
Arch Pathol Lab Med
1989
.
113
:
414
416
.
Zavala-Pompa
,
A.
,
J. Y.
Ro
, and
A. K.
el Naggar
.
et al
.
Tubular seminoma: an immunohistochemical and DNA flow-cytometric study of four cases.
Am J Clin Pathol
1994
.
102
:
397
401
.
Talerman
,
A.
Tubular seminoma.
Arch Pathol Lab Med
1989
.
113
:
1204
.
Takeshima
,
Y.
,
N.
Sanda
,
K.
Yoneda
, and
K.
Inai
.
Tubular seminoma of the testis.
Pathol Int
1999
.
49
:
676
679
.
Henley
,
J. D.
,
R. H.
Young
,
C. L.
Wade
, and
T. M.
Ulbright
.
Seminomas with exclusive intertubular growth: a report of 12 clinically and grossly inconspicuous tumors.
Am J Surg Pathol
2004
.
28
:
1163
1168
.
Ulbright
,
T. M.
and
R. H.
Young
.
Seminoma with tubular, microcystic, and related patterns: a study of 28 cases of unusual morphologic variants that often cause confusion with yolk sac tumor.
Am J Surg Pathol
2005
.
29
:
500
505
.
Florentine
,
B. D.
,
A. A.
Roscher
,
J.
Garrett
, and
N. E.
Warner
.
Necrotic seminoma of the testis: establishing the diagnosis with Masson trichrome stain and immunostains.
Arch Pathol Lab Med
2002
.
126
:
205
206
.
Kademian
,
M.
,
A.
Bosch
,
W. L.
Caldwell
, and
W.
Jaeschke
.
Anaplastic seminoma.
Cancer
1977
.
40
:
3082
3086
.
Cockburn
,
A. G.
,
D.
Vugrin
,
M.
Batata
,
S.
Hajdu
, and
W. F.
Whitmore
.
Poorly differentiated (anaplastic) seminoma of the testis.
Cancer
1984
.
53
:
1991
1994
.
Bobba
,
V. S.
,
B. B.
Mittal
,
S. V.
Hoover
, and
A.
Kepka
.
Classical and anaplastic seminoma: difference in survival.
Radiology
1988
.
167
:
849
852
.
Johnson
,
D. E.
,
J. J.
Gomez
, and
A. G.
Ayala
.
Anaplastic seminoma.
J Urol
1975
.
114
:
80
82
.
Zuckman
,
M. H.
,
G.
Williams
, and
H. S.
Levin
.
Mitosis counting in seminoma: an exercise of questionable significance.
Hum Pathol
1988
.
19
:
329
335
.
Hori
,
K.
,
K.
Uematsu
,
H.
Yasoshima
,
K.
Sakurai
, and
A.
Yamada
.
Contribution of cell proliferative activity to malignancy potential in testicular seminoma.
Pathol Int
1997
.
47
:
282
287
.
Bailey
,
D.
,
A.
Marks
,
M.
Stratis
, and
R.
Baumal
.
Immunohistochemical staining of germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody.
Mod Pathol
1991
.
4
:
167
171
.
Leroy
,
X.
,
D.
Augusto
,
E.
Leteurtre
, and
B.
Gosselin
.
CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma.
J Histochem Cytochem
2002
.
50
:
283
285
.
Tickoo
,
S. K.
,
B.
Hutchinson
, and
J.
Bacik
.
et al
.
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features.
Int J Surg Pathol
2002
.
10
:
23
32
.
Ferreiro
,
J. A.
Ber-H2 expression in testicular germ cell tumors.
Hum Pathol
1994
.
25
:
522
524
.
Jacobsen
,
G. K.
and
M.
Jacobsen
.
Alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in testicular germ cell tumours: a prospective immunohistochemical study.
Acta Pathol Microbiol Immunol Scand A
1983
.
91
:
165
176
.
Jones
,
T. D.
,
T. M.
Ulbright
,
J. N.
Eble
,
L. A.
Baldridge
, and
L.
Cheng
.
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma.
Am J Surg Pathol
2004
.
28
:
935
940
.
Cheng
,
L.
Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry.
Cancer
2004
.
101
:
2006
2010
.
Cheville
,
J. C.
,
S.
Rao
,
K. A.
Iczkowski
,
C. M.
Lohse
, and
V. S.
Pankratz
.
Cytokeratin expression in seminoma of the human testis.
Am J Clin Pathol
2000
.
113
:
583
588
.
International Germ Cell Consensus
Classification: a prognostic factor-based staging system for metastatic germ cell cancers: International Germ Cell Cancer Collaborative Group.
J Clin Oncol
1997
.
15
:
594
603
.
Testis (ICD-0 C62).
In: Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. 5th ed. New York, NY: Wiley-Liss; 1997:174–179
.
Chung
,
P.
,
C.
Parker
, and
T.
Panzarella
.
et al
.
Surveillance in stage I testicular seminoma.
Can J Urol
2002
.
9
:
1637
1640
.
Warde
,
P.
,
L.
Specht
, and
A.
Horwich
.
et al
.
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
J Clin Oncol
2002
.
20
:
4448
4452
.
von der
,
Maase H.
,
L.
Specht
, and
G. K.
Jacobsen
.
et al
.
Surveillance following orchidectomy for stage I seminoma of the testis.
Eur J Cancer
1993
.
29A
:
1931
1934
.
Thomas
,
G. M.
Over 20 years of progress in radiation oncology: seminoma.
Semin Radiat Oncol
1997
.
7
:
135
145
.
Porcaro
,
A. B.
,
S. Z.
Antoniolli
,
N.
Maffei
,
P.
Beltrami
,
M. A.
Bassetto
, and
P.
Curti
.
Management of testicular seminoma advanced disease: report on 14 cases and review of the literature.
Arch Ital Urol Androl
2002
.
74
:
81
85
.
Talerman
,
A.
Spermatocytic seminoma: clinicopathological study of 22 cases.
Cancer
1980
.
45
:
2169
2176
.
Stoop
,
H.
,
R.
van Gurp
, and
R.
de Krijger
.
et al
.
Reactivity of germ cell maturation stage-specific markers in spermatocytic seminoma: diagnostic and etiological implications.
Lab Invest
2001
.
81
:
919
928
.
Verdorfer
,
I.
,
H.
Rogatsch
,
A.
Tzankov
,
H.
Steiner
, and
G.
Mikuz
.
Molecular cytogenetic analysis of human spermatocytic seminomas.
J Pathol
2004
.
204
:
277
281
.
Chung
,
P. W.
,
A. J.
Bayley
, and
J.
Sweet
.
et al
.
Spermatocytic seminoma: a review.
Eur Urol
2004
.
45
:
495
498
.
Aristizabal
,
S.
,
J. R.
Davis
,
R. C.
Miller
,
M. J.
Moore
, and
M. L. M.
Boone
.
Bilateral primary germ cell testicular tumors: report of four cases and review of the literature.
Cancer
1978
.
42
:
591
597
.
Gilbert
,
J. B.
and
J. B.
Hamilton
.
Studies in malignant tumor of the testis, IV: bilateral testicular cancer. Incidence, nature, and bearing upon management of the patient with a single testicular cancer.
Cancer Res
1942
.
21
:
125
129
.
Steiner
,
H.
,
C.
Gozzi
,
I.
Verdorfer
,
G.
Mikuz
,
G.
Bartsch
, and
A.
Hobisch
.
Metastatic spermatocytic seminoma—an extremely rare disease.
Eur Urol
2006
.
49
:
183
186
.
Matoska
,
J.
,
D.
Ondrus
, and
M.
Hornak
.
Metastatic spermatocytic seminoma. A case report with light microscopic, ultrastructural, and immunohistochemical findings.
Cancer
1988
.
62
:
1197
1201
.
True
,
L. D.
,
C. N.
Otis
,
W.
Delprado
,
R. E.
Scully
, and
J.
Rosai
.
Spermatocytic seminoma of testis with sarcomatous transformation: a report of five cases.
Am J Surg Pathol
1988
.
12
:
75
82
.
Matoska
,
J.
and
A.
Talerman
.
Spermatocytic seminoma associated with rhabdomyosarcoma.
Am J Clin Pathol
1990
.
94
:
89
95
.
Floyd
,
C.
,
A. G.
Ayala
,
C. J.
Logothetis
, and
E. G.
Silva
.
Spermatocytic seminoma with associated sarcoma of the testis.
Cancer
1988
.
61
:
409
414
.
Burke
,
A. P.
and
F. K.
Mostofi
.
Spermatocytic seminoma: a clinicopathologic study of 79 cases.
J Urol Pathol
1993
.
1
:
21
32
.
Ro
,
J. Y.
,
D. J.
Grignon
,
M. B.
Amin
, and
A. G.
Ayala
.
Atlas of Surgical Pathology of the Male Reproductive Tract.
1st ed. Philadelphia, Pa: WB Saunders; 1997:115– 146
.
Albores-Saavedra
,
J.
,
H.
Huffman
,
I.
Alvarado-Cabrero
, and
A. G.
Ayala
.
Anaplastic variant of spermatocytic seminoma.
Hum Pathol
1996
.
27
:
650
655
.
Dekker
,
I.
,
T.
Rozeboom
,
J.
Delemarre
,
A.
Dam
, and
J. W.
Oosterhuis
.
Placental-like alkaline phosphatase and DNA flow cytometry in spermatocytic seminoma.
Cancer
1992
.
69
:
993
996
.
Cummings
,
O. W.
,
T. M.
Ulbright
,
J. N.
Eble
, and
L. M.
Roth
.
Spermatocytic seminoma: an immunohistochemical study.
Hum Pathol
1994
.
25
:
54
59
.
Decaussin
,
M.
,
A.
Borda
, and
R.
Bouvier
.
et al
.
[Spermatocytic seminoma: a clinicopathological and immunohistochemical study of 7 cases].
Ann Pathol
2004
.
24
:
161
166
.
Zeeman
,
A. M.
,
H.
Stoop
, and
M.
Boter
.
et al
.
VASA is a specific marker for both normal and malignant human germ cells.
Lab Invest
2002
.
82
:
159
166
.
Pendlebury
,
S.
,
A.
Horwich
,
D. P.
Dearnaley
,
J.
Nicholls
, and
C.
Fisher
.
Spermatocytic seminoma: a clinicopathological review of ten patients.
Clin Oncol (R Coll Radio)
1996
.
8
:
316
318
.
Mostofi
,
F. K.
,
I. A.
Sesterhenn
, and
C. J. Jr
Davis
.
Developments in histopathology of testicular germ cell tumors.
Semin Urol
1988
.
6
:
171
188
.
Rodriguez
,
P. N.
,
G. R.
Hafez
, and
E. M.
Messing
.
Nonseminomatous germ cell tumor of the testicle: does extensive staging of the primary tumor predict the likelihood of metastatic disease?
J Urol
1986
.
136
:
604
608
.
Berney
,
D. M.
,
A.
Lee
,
S. J.
Randle
,
S.
Jordan
,
J.
Shamash
, and
R. T.
Oliver
.
The frequency of intratubular embryonal carcinoma: implications for the pathogenesis of germ cell tumours.
Histopathology
2004
.
45
:
155
161
.
Battifora
,
H.
,
K.
Sheibani
,
R. R.
Tubbs
,
M. I.
Kopinski
, and
T. T.
Sun
.
Antikeratin antibodies in tumor diagnosis: distinction between seminoma and embryonal carcinoma.
Cancer
1984
.
54
:
843
848
.
Mostofi
,
F. K.
,
I. A.
Sesterhenn
, and
C. J. Jr
Davis
.
Immunopathology of germ cell tumors of the testis.
Semin Diagn Pathol
1987
.
4
:
320
341
.
Kaplan
,
G. W.
,
W. C.
Cromie
,
P. P.
Kelalis
,
I.
Silber
, and
E. S. Jr
Tank
.
Prepubertal yolk sac testicular tumors—report of the testicular tumor registry.
J Urol
1988
.
140
:
1109
1112
.
Ross
,
J. H.
,
L.
Rybicki
, and
R.
Kay
.
Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
J Urol
2002
.
168
:
1675
1678
.
Talerman
,
A.
The incidence of yolk sac tumor (endodermal sinus tumor) elements in germ cell tumors of the testis in adults.
Cancer
1975
.
36
:
211
215
.
Talerman
,
A.
,
W. G.
Haije
, and
L.
Baggerman
.
Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: correlation between endodermal sinus (yolk sac) tumor and raised serum AFP.
Cancer
1980
.
46
:
380
385
.
Wu
,
J. T.
,
L.
Book
, and
K.
Sudar
.
Serum alpha fetoprotein (AFP) levels in normal infants.
Pediatr Res
1981
.
15
:
50
52
.
Ulbright
,
T. M.
,
M. B.
Amin
, and
R. H.
Young
.
Tumors of the Testis, Adnexa, Spermatic Cord, and Scrotum.
Washington, DC: Armed Forces Institute of Pathology; 1999. Atlas of Tumor Pathology; 3rd series, fascicle 25
.
Ulbright
,
T. M.
,
L. M.
Roth
, and
C. A.
Brodhecker
.
Yolk sac differentiation in germ cell tumors: a morphologic study of 50 cases with emphasis on hepatic, enteric, and parietal yolk sac features.
Am J Surg Pathol
1986
.
10
:
151
164
.
Eglen
,
D. E.
and
T. M.
Ulbright
.
The differential diagnosis of yolk sac tumor and seminoma: usefulness of cytokeratin, alpha-fetoprotein, and alpha-1-antitrypsin immunoperoxidase reactions.
Am J Clin Pathol
1987
.
88
:
328
332
.
Mostofi
,
F. K.
Histological change ostensibly induced by therapy in the metastasis of germ cell tumors of testis.
Prog Clin Biol Res
1985
.
203
:
47
60
.
Zynger
,
D. L.
,
N. D.
Dimov
,
C.
Luan
,
B. T.
Teh
, and
X. J.
Yang
.
Glypican 3: a novel marker in testicular germ cell tumors.
Am J Surg Pathol
2006
.
30
:
1570
1575
.
Grady
,
R. W.
,
J. H.
Ross
, and
R.
Kay
.
Patterns of metastatic spread in prepubertal yolk sac tumor of the testis.
J Urol
1995
.
153
:
1259
1261
.
Lopez
,
J. I.
and
J. C.
Angulo
.
Burned-out tumour of the testis presenting as retroperitoneal choriocarcinoma.
Int Urol Nephrol
1994
.
26
:
549
553
.
Ulbright
,
T. M.
,
R. H.
Young
, and
R. E.
Scully
.
Trophoblastic tumors of the testis other than classic choriocarcinoma: “monophasic” choriocarcinoma and placental site trophoblastic tumor: a report of two cases.
Am J Surg Pathol
1997
.
21
:
282
288
.
Suurmeijer
,
A. J.
,
J. A.
Gietema
, and
H. J.
Hoekstra
.
Placental site trophoblastic tumor in a late recurrence of a nonseminomatous germ cell tumor of the testis.
Am J Surg Pathol. 2004;28:–830833
.
Ulbright
,
T. M.
,
J. D.
Henley
,
O. W.
Cummings
,
R. S.
Foster
, and
L.
Cheng
.
Cystic trophoblastic tumor: a nonaggressive lesion in postchemotherapy resections of patients with testicular germ cell tumors.
Am J Surg Pathol
2004
.
28
:
1212
1216
.
Pelkey
,
T. J.
,
H. F. Jr
Frierson
,
S. E.
Mills
, and
M. H.
Stoler
.
Detection of the alpha-subunit of inhibin in trophoblastic neoplasia.
Hum Pathol
1999
.
30
:
26
31
.
Singer
,
G.
,
R. J.
Kurman
,
M. T.
McMaster
, and
I.
Shih
.
HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis.
Am J Surg Pathol
2002
.
26
:
914
920
.
Clark
,
R. K.
and
I.
Damjanov
.
Intermediate filaments of human trophoblast and choriocarcinoma cell lines.
Virchows Arch A Pathol Anat Histopathol
1985
.
407
:
203
208
.
Lind
,
H. M.
and
P.
Haghighi
.
Carcinoembryonic antigen staining in choriocarcinoma.
Am J Clin Pathol
1986
.
86
:
538
540
.
McKendrick
,
J. J.
,
J.
Theaker
, and
G. M.
Mead
.
Nonseminomatous germ cell tumor with very high serum human chorionic gonadotropin.
Cancer
1991
.
67
:
684
689
.
Bredael
,
J. J.
,
D.
Vugrin
, and
W. F. Jr
Whitmore
.
Autopsy findings in 154 patients with germ cell tumors of the testis.
Cancer
1982
.
50
:
548
551
.
von Hochstetter
,
A. R.
and
C. E.
Hedinger
.
The differential diagnosis of testicular germ cell tumors in theory and practice: a critical analysis of two major systems of classification and review of 389 cases.
Virchows Arch A Pathol Anat Histol
1982
.
396
:
247
277
.
Schneider
,
D. T.
,
A. E.
Schuster
, and
M. K.
Fritsch
.
et al
.
Genetic analysis of childhood germ cell tumors with comparative genomic hybridization.
Klin Padiatr
2001
.
213
:
204
211
.
Brosman
,
S. A.
Testicular tumors in prepubertal children.
Urology
1979
.
13
:
581
588
.
Leibovitch
,
I.
,
R. S.
Foster
,
T. M.
Ulbright
, and
J. P.
Donohue
.
Adult primary pure teratoma of the testis: the Indiana experience.
Cancer
1995
.
75
:
2244
2250
.
Ulbright
,
T. M.
and
J. R.
Srigley
.
Dermoid cyst of the testis: a study of five postpubertal cases, including a pilomatrixoma-like variant, with evidence supporting its separate classification from mature testicular teratoma.
Am J Surg Pathol
2001
.
25
:
788
793
.
Mosharafa
,
A. A.
,
R. S.
Foster
, and
B. C.
Leibovich
.
et al
.
Histology in mixed germ cell tumors: is there a favorite pairing?
J Urol
2004
.
171
:
1471
1473
.
Mostofi
,
F. K.
Proceedings: testicular tumors: epidemiologic, etiologic, and pathologic features.
Cancer
1973
.
32
:
1186
1201
.
Ro
,
J. Y.
,
F. H.
Dexeus
,
A.
el Naggar
, and
A. G.
Ayala
.
Testicular germ cell tumors: clinically relevant pathologic findings.
Pathol Annu
1991
.
26
:(
pt 2
).
59
87
.
Moul
,
J. W.
and
A.
Heidenreich
.
Prognostic factors in low-stage nonseminomatous testicular cancer.
Oncology (Williston Park)
1996
.
10
:
1359
1368
.
1374
.
Heidenreich
,
A.
,
I. A.
Sesterhenn
,
F. K.
Mostofi
, and
J. W.
Moul
.
Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Cancer
1998
.
83
:
1002
1011
.
Amato
,
R. J.
,
J. Y.
Ro
,
A. G.
Ayala
, and
D. A.
Swanson
.
Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Urology
2004
.
63
:
144
148
.
Heidenreich
,
A.
,
I. A.
Sesterhenn
,
F. K.
Mostofi
,
J. W.
Moul
, and
U. H.
Engelmann
.
[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors: implications for risk-adjusted therapy].
Urologe. A
1999
.
38
:
168
178
.
Bosl
,
G. J.
,
R.
Gluckman
, and
N. L.
Geller
.
et al
.
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.
J Clin Oncol
1986
.
4
:
1493
1499
.
Ulbright
,
T. M.
,
P. J.
Loehrer
,
L. M.
Roth
,
L. H.
Einhorn
,
S. D.
Williams
, and
S. A.
Clark
.
The development of non-germ cell malignancies within germ cell tumors: a clinicopathologic study of 11 cases.
Cancer
1984
.
54
:
1824
1833
.
Michael
,
H.
Nongerm cell tumors arising in patients with testicular germ cell tumors.
J Urol Pathol
1998
.
9
:
39
60
.
Comiter
,
C. V.
,
A. S.
Kibel
,
J. P.
Richie
,
M. R.
Nucci
, and
A. A.
Renshaw
.
Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases.
J Urol
1998
.
159
:
859
863
.
Ahmed
,
T.
,
G. J.
Bosl
, and
S. I.
Hajdu
.
Teratoma with malignant transformation in germ cell tumors in men.
Cancer
1985
.
56
:
860
863
.
Michael
,
H.
,
M. T.
Hull
,
T. M.
Ulbright
,
R. S.
Foster
, and
K. D.
Miller
.
Primitive neuroectodermal tumors arising in testicular germ cell neoplasms.
Am J Surg Pathol
1997
.
21
:
896
904
.
Ro
,
J. Y.
,
R. J.
Amato
, and
A. G.
Ayala
.
What does the pathology report really mean?
Semin Urol Oncol
1996
.
14
:
2
7
.
Nazeer
,
T.
,
J. Y.
Ro
,
R. J.
Amato
,
Y. W.
Park
,
N. G.
Ordonez
, and
A. G.
Ayala
.
Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases.
Oncol Rep
1998
.
5
:
1425
1429
.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Alberto G. Ayala, MD, Department of Pathology, The Methodist Hospital, Weill Medical College of Cornell University, 6565 Fannin St, Houston, TX 77030 (aayala@tmh.tmc.edu)